In Vivo Hybridization Chain Reaction: proof of principle Xenograft mouse study to demonstrate a nanotechnology based conditional cancer therapy, selectively killing mutant cells, while leaving healthy cells untouched.
In Vivo Hybridization Chain Reaction: proof of principle Xenograft mouse study to demonstrate a nanotechnology based conditional cancer therapy, selectively killing mutant cells, while leaving healthy cells untouched.
体内杂交链式反应：原理证明异种移植小鼠研究展示了基于纳米技术的条件性癌症疗法，选择性杀死突变细胞，同时不影响健康细胞。
批准号：
158972173
负责人：
Dr. Tobias Heinen
金额：
$0.0万
依托单位国家：
德国
项目类别：
Research Fellowships
财政年份：
2009
资助国家：
德国
项目状态：
已结题
起止时间：
2008-12-31 至 2011-12-31
中文摘要
翻译
体内杂交链式反应（HCR）是一种基于核酸的纳米技术的新方法。两个热力学亚稳态小条件RNA （scRNAs）形成长双链RNA聚合物，只有当诊断性RNA靶标存在时。这种方法可以在体外选择性地杀死癌细胞，而不影响其他细胞。目前的目标是开发一种有条件的治疗癌症的方法，这种方法可以识别并选择性地破坏肿瘤。因此，scrna将在异种移植小鼠模型中进行测试。最先进的纳米颗粒rna递送系统被用于在体内将scrna递送到肿瘤。
英文摘要
In Vivo Hybridization Chain Reaction: triggered therapeutics for targeted destruction of cancer cellsHybridization Chain Reaction (HCR) is a new method in nucleic acid based nanotechnology. Two thermodynamically metastable small conditional RNAs (scRNAs) form a long double-stranded RNA polymer, only if a diagnostic RNA target is present. This method can be adapted to selectively kill cancer cells in vitro while leaving other cells untouched. The current aim is to develop a conditional therapy for the treatment of cancer, which recognizes and selectively destroys tumors. Therefore, scRNAs are to be tested in xenograft mouse models. State of the art nanoparticle RNA-delivery systems are used to deliver scRNAs to tumors in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金
